Long term effect of IVIg and CTX treatment in patients with multifocal motor neuropathy

Patient NoAge/SexDuration before treatmentMonths of treatmentTotal months of follow upMRC score1-150Rankin scoreNerves with PMCBAntiglycolipid titres1-151
IVIgCTXBefore treatmentAt last follow upBefore treatmentAt last follow upBefore treatmentAt last follow upBefore treatmentAt last follow up
148/M10 y1→133→255566831-152→771-153 21211-152→21-153 640 (GM1)Neg1-152 1-153
226/F5 y1→445→446137831-152→811-153 41401-152→11-153 NegNeg
351/F4 y1→363→454581851-152→761-153 211-152→21-153 311-152→21-153 40960 (aGM1)409601-152 1-153
429/M3 months1→91→134689951-152→891-153 211-152→21-153 201-152→21-153 ⊘2560 (GD1a)Neg1-152 1-153
534/M4 y1→371→373779862222⊘5120 (GD1a)2560
660/F10y1→371→373765803220NegNeg
Mean29.331.746.869.585.31-152 1-154
Median211-152
Total1541-152 **
  • 1-150 Calculated in the 20 more severely affected muscles.

  • 1-151 IgM titres (inverse of serum dilution) except ⊘ (IgG). Normal upper limits: GM=1/320; asialoGM1 (aGM1)=1/5120; GD1a=1/640.

  • 1-152 At last follow up before relapse.

  • 1-153 At relapse, after the end of treatment.

  • 1-154  t=−2.476, P=0.0561; t=2.907, P=0.0335.** t=3.379, P=0.0197 (Student’s t test for paired data).

  • PMCB=partial motor conduction block.